Metacognitive Remediation Therapy: Clinical Benefits, Treatment Satisfaction, and Cost-Effectiveness among Individuals with First-Episode Psychosis

Poster C43, Wednesday, October 10, 11:30 am - 1:00 pm, Essex Ballroom

Nicholas J. K. Breitborde1, Jacob G. Pine1, Amy K. Ferketich1, Aubrey M. Moe1; 1The Ohio State University

Within psychotherapy research, there is growing interest in psychosocial interventions that target metacognitive skill development as the mechanism for therapeutic change. One example of such an intervention—metacognitive remediation therapy (MCR)—is a form of individual psychotherapy designed to facilitate growth in two components of metacognition (i.e., knowledge of cognition and regulation of cognition) as well as address common barriers that may hinder implementation of these metacognitive skills in real-world settings (e.g., difficulties in arousal regulation and deficits in motivation/self-efficacy). Within this presentation, we will review data from past studies of MCR among individuals with first-episode psychosis demonstrating the beneficial effects of this intervention on metacognitive functioning and subsequent downstream improvements in health-related quality of life and cognitive, occupational/educational, and social functioning. Moreover, we will highlight recent research on treatment satisfaction among individuals with first-episode psychosis participating in MCR and the cost-effectiveness of incorporating MCR within Coordinated Specialty Care programs for first-episode psychosis. Finally, we will review data from two recent demonstration projects investigating the feasibility of modified versions of MCR (i) for delivery in inpatient psychiatric settings and (ii) to promote smoking cessation among individuals with psychotic disorders. In total, the results of these studies highlight the promise of MCR as a clinically-beneficial and cost-effective treatment for individuals with first-episode psychosis.

Topic Area: Psychosocial Interventions

Back to Poster Schedule